Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

2024 Top 100 Pharmaceutical Industry Comprehensive Competitiveness Ranking Released!

Published Time:

2024-08-10

 

On August 10th, at the West Pharmaceutical Banquet themed "Beyond Glory, Sparkling Stars," Zhongkang Industry Research Institute released the 2024 Pharmaceutical Industry Comprehensive Competitiveness Index, and based on the index, generated the "2024 Pharmaceutical Industry Comprehensive Competitiveness Top 100 List" , 100 benchmark companies received industry-wide accolades, composing a song of glory.

 

The Pharmaceutical Industry Comprehensive Competitiveness Index is based on a scientifically quantified model by Zhongkang Industry Research Institute, from market/valuation, commercialization capabilities, and R&D capabilities, three dimensions, comprehensively measuring the company's overall competitiveness, objectively, comprehensively, and multi-dimensionally reflecting the company's overall competitiveness.

 

 

01

Compilation Method of the Pharmaceutical Industry Comprehensive Competitiveness Index

 

Different from selections based on operating income as a single indicator, the index compilation of Zhongkang Industry Research Institute selects "market/valuation" as the primary indicator, commercialization capabilities and R&D capabilities as secondary indicators, through the evaluation of the company's "market/valuation", "commercialization capabilities", and "R&D capabilities", three dimensions to establish an evaluation model to measure the company's comprehensive competitiveness index.

 

"Market/valuation" is a concentrated reflection of the company's revenue scale, growth ability, profitability, market recognition, and other comprehensive factors, and therefore serves as the core indicator for company evaluation. The company's commercialization capabilities and R&D capabilities are both evaluated from the two dimensions of resource input and output.

 

 

02

Huadong Medicine, AstraZeneca, and CSPC Pharmaceutical ranked among the top three in the Top 100.

 

Entering the top 10 companies in the "2024 Pharmaceutical Industry Comprehensive Competitiveness Top 100" are Huadong Medicine, AstraZeneca, CSPC Pharmaceutical, China Biologic Products, BeiGene, Yangtze River Pharmaceutical, Qilu Pharmaceutical, Sinopharm Group, Fosun Pharma, and Novartis. 。 The rankings of the top 10 pharmaceutical companies have changed slightly, with CSPC Pharmaceutical, BeiGene, and Qilu Pharmaceutical rising one place respectively compared to last year.

 

The Top 100 list is mainly composed of domestic companies. In terms of the number of companies listed, domestic companies account for approximately 85%, and multinational companies account for 15%. 。 From the perspective of main business, 52 companies mainly engaged in chemical preparations are listed, 15 companies mainly engaged in biological products, 26 companies mainly engaged in traditional Chinese medicine, and 7 companies mainly engaged in chemical raw materials.

 

In terms of total pharmaceutical industry revenue, the total revenue of chemical preparation companies accounts for approximately 61% of the total pharmaceutical industry revenue of the Top 100 list, chemical raw material companies account for 7%, biological product companies account for 10%, and traditional Chinese medicine companies account for 21%.

 

Currently, in the face of profound and complex changes in the international environment, the pharmaceutical industry still faces many challenges and needs to actively respond to industry transformation and upgrading, striving to move towards a new stage of high-quality development. Thanks to the inherent resilience, huge potential, and abundant vitality of China's pharmaceutical industry, the pharmaceutical industry is expected to return to stable growth in the future.

 

 

This article is from: New Kangjie